Nonchemotherapy drug‐induced cytopenias: A cost‐of‐illness study using the microcosting methodology based on real‐world data

Documenti analoghi

• The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations
  di: Andrej Belančić, et al.
  Pubblicazione: (2026)
• Cost–utility of lifileucel in patients with advanced melanoma after progression on immune checkpoint inhibitors And targeted therapies: a middle‐income economy setting
  di: Svetlana Obrenovic, et al.
  Pubblicazione: (2025)
• Temporal effects of errors in estimating kidney function after critical illness on drug dosing categories
  di: Ryusei Mikami, et al.
  Pubblicazione: (2025)
• Understanding factors that influence the drug choice of prescribers: A Q‐methodology study
  di: Mariëlle G. Hartjes, et al.
  Pubblicazione: (2025)
• Evaluating the capability of ChatGPT in predicting drug–drug interactions: Real‐world evidence using hospitalized patient data
  di: Ramya Padmavathy Radha Krishnan, et al.
  Pubblicazione: (2024)